Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Dermatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)
INTERVENTIONAL
Inicio: 31 de may de 2022
ID: NCT05398445
Completado
Fase 2
ClinicalTrials.gov
Effisayil™ 2: Multi-center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb Dose-finding Study to Evaluate Efficacy and Safety of BI 655130 (Spesolimab) Compared to Placebo in Preventing Generalized Pustular Psoriasis (GPP) Flares in Patients With History of GPP.
INTERVENTIONAL
Inicio: 4 de jun de 2020
ID: NCT04399837
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of Dupilumab in Patients With Chronic Inducible Cold Urticaria Who Remain Symptomatic Despite the Use of H1-antihistamine Treatment
INTERVENTIONAL
Inicio: 10 de dic de 2020
ID: NCT04681729
Completado
Fase 3
ClinicalTrials.gov
A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
INTERVENTIONAL
Inicio: 12 de sept de 2013
ID: NCT01909453
Completado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)
INTERVENTIONAL
Inicio: 19 de sept de 2017
ID: NCT03268005
Completado
Fase 3
ClinicalTrials.gov
Effect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes
INTERVENTIONAL
Inicio: 15 de jun de 2021
ID: NCT04916470
Completado
Fase 3
ClinicalTrials.gov
A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis
INTERVENTIONAL
Inicio: 22 de ago de 2016
ID: NCT02662985
Activo, no recluta
ClinicalTrials.gov
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
OBSERVATIONAL
Inicio: 21 de jun de 2007
ID: NCT00508547
Terminado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00503698
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
INTERVENTIONAL
Inicio: 27 de feb de 2023
ID: NCT05723198
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
INTERVENTIONAL
Inicio: 1 de jun de 2011
ID: NCT01365455
Completado
Fase 3
ClinicalTrials.gov
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)
INTERVENTIONAL
Inicio: 20 de sept de 2013
ID: NCT01952145
Completado
Fase 4
ClinicalTrials.gov
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids
INTERVENTIONAL
Inicio: 16 de dic de 2016
ID: NCT02953821
Completado
Fase 4
ClinicalTrials.gov
A 20 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group Comparison of Twice Daily Subject Driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Versus Twice Daily Investigator-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Both in Combination With Metformin in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin Analogues
INTERVENTIONAL
Inicio: 1 de sept de 2011
ID: NCT01427920
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Phase 2 Study of Rilzabrutinib Followed by an Open-label Extension Phase in Patients With Moderate-to-severe Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment
INTERVENTIONAL
Inicio: 24 de nov de 2021
ID: NCT05107115
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase 2b Dose-finding Study to Investigate the Efficacy, Safety and Tolerability of LOU064 in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines
INTERVENTIONAL
Inicio: 6 de jun de 2019
ID: NCT03926611
Completado
Fase 3
ClinicalTrials.gov
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
INTERVENTIONAL
Inicio: 4 de ago de 2014
ID: NCT02128932
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies
INTERVENTIONAL
Inicio: 9 de dic de 2022
ID: NCT05513001
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
INTERVENTIONAL
Inicio: 6 de may de 2025
ID: NCT06747351
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
INTERVENTIONAL
Inicio: 8 de nov de 2023
ID: NCT06130566
Anterior
1
...
10
11
12
...
434
Siguiente
Filtros